Value proposition

Developing selective inhibitors of CTPS1 for patients with cancer and auto-immune diseases

Step Pharma is the world leader in the discovery and development of inhibitors of CTPS1 (cytidine triphosphate synthase 1) for the treatment of cancer and autoimmune diseases.
Step Pharma’s lead program STP938 is a potent, selective, oral inhibitor of CTPS1 with demonstrated potent anti-tumor activity in models of leukemia and lymphoma. STP938 will enter clinical development in 2022 for the treatment of relapsed and refractory T-cell and B-cell lymphoma.